Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis

Togashi, Junichi; Sugawara, Yasuhiko; Tamura, Sumihito; Kaneko, Junichi; Yamashiki, Noriyo; Aoki, Taku; Hasegawa, Kiyoshi; Kokudo, Norihiro

doi:10.5582/bst.2011.v5.2.57

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that RATG-based induction immunosuppression could be safely used in adult OLT recipients with excellent survival, low rejection rates, and a comparably acceptable incidence of side effects [20]. Experts from the University of Tokyo in Japan conducted an observational study to evaluate the efficacy and safety of basiliximab as rescue therapy for the treatment of acute cellular rejection [41]. In contrast to 11 patients who received steroid therapy for acute cellular rejection, there were no significant immediate adverse effects in the basiliximab group which underwent liver transplantation for HCV cirrhosis [41].…”

Section: Discussionmentioning

confidence: 99%

“…Experts from the University of Tokyo in Japan conducted an observational study to evaluate the efficacy and safety of basiliximab as rescue therapy for the treatment of acute cellular rejection [41]. In contrast to 11 patients who received steroid therapy for acute cellular rejection, there were no significant immediate adverse effects in the basiliximab group which underwent liver transplantation for HCV cirrhosis [41]. In addition, recent studies have shown that immunosuppression with low-dose daclizumab and delayed initiation of Tac had significant benefits in preserving renal function after OLT [42].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

Lü

et al. 2014

Hepatol Int

View full text Add to dashboard Cite

To evaluate the efficacy and safety of early steroid withdrawal or steroid avoidance in the tacrolimus (Tac)-based immunosuppressive regimen for liver transplant recipients. According to the requirements of the Cochrane systematic review, a thorough literature search was performed in the PubMed/MEDLINE and Cochrane electronic databases between 1995 and 2011 using the key words “liver transplantation,” “Tac,” and “steroid free” or “steroid withdrawal,” restricting articles to the English language. Data were processed for a meta-analysis by Stata 12 software. Altogether 17 prospective randomized controlled trials containing 1,980 transplanted patients were included in this study. The overall pooled RR estimates of 1-, 2-, 3-, and 5-year patient and graft survival rates were 0.985, 0.998, 0.995, and 1.100 (95 % CI 0.925–1.048, 0.934–1.067, 0.894–1.107, and 0.968–1.250, respectively), as well as 0.998, 0.993, 0.945, and 1.053, respectively (95 % CI 0.928–1.072, 0.902–1.092, 0.833–1.072, and 0.849–1.307, respectively). The other pooled RR estimates of acute rejection and chronic rejection rates for all enrolled studies were 1.077 and 0.311 (95 % CI 0.864–1.343 and 0.003–37.207). As for secondary predictors, the pooled RR estimates such as HCV recurrence, HCC recurrence, diabetes, hypertension, kidney dysfunction, bacterial infection, and CMV were 1.101, 1.403, 1.836, 1.607, 0.842, 1.096, and 2.280, respectively (95 % CI 0.964–1.257, 0.422–4.688, 1.294–2.606, 0.926–1.228, 0.693–1.022, 0.783–1.533, and 1.500–3.465, respectively). There were no differences between the steroid group and steroid-free group for all clinical observational indices except for the incidence of diabetes (p = 0.001) and CMV infection (p < 0.001). In summary, our study indicate that rapid discontinuation of steroid in the Tac-based immunosuppressive regimen may not lead to an increased risk of morbidity and rejection rate.Electronic supplementary materialThe online version of this article (doi:10.1007/s12072-014-9523-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

Lü

et al. 2014

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…However, its role in treating pre-existing rejection has not been elucidated. Several research studied the efficiency of IL-2R on reversing an established rejection (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). These studies indicated that IL-2R mAb could be used safely and effectively in various situations among solid transplantation recipients, without increasing the incidence of bacterial/fungal/CMV infection, such as for steroid-resistant rejection (SRR) and rejection in HCV-positive recipients after liver transplantation, SRR, severe acute-hybrid rejection, and acute rejection after kidney transplantation.…”

Section: Discussionmentioning

confidence: 99%

Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report

Chen

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

A 66-year-old Chinese man underwent a deceased donor kidney transplantation. Induction-immunosuppressive protocol consisted of basiliximab (BAS) and methyl prednisolone (MP), followed by maintenance immunosuppression with cyclosporin (CsA), mycophenolate mofetil (MMF), and prednisone (PED). The patient’s post-transplantation course was almost uneventful, and the graft was functioning well [serum creatinine (Scr) 2.15 mg/dL]. The MMF and CsA doses were decreased 1-month post-operative as the BK virus activation was serologically positive. His Scr was elevated to 2.45 mg/dL 45 days after the transplant. A graft biopsy showed BKV nephropathy (BKVN) and acute T cell–mediated rejection (TCMR) Banff grade IIA (I2, t2, ptc2, v1, c4d1, g0, and SV40 positive). The conventional anti-rejection therapy could deteriorate his BKVN, therefore, we administered BAS to eliminate activated graft-infiltrating T cells and combined with low-dose steroid. He responded well to the therapy after two doses of BAS were given, and the kidney graft status has been stable (recent Scr 2.1 mg/dL).

show abstract

“…The incidence of infection and other adverse events was similar across the two treatment groups [65]. At present, the main indication for basiliximab in adults is renal dysfunction at the time of liver transplantation in order to delay the introduction of calcineurin inhibitors [66] but basiliximab has also been used as a rescue treatment for acute rejection in patients who received a transplant because of hepatitis C cirrhosis [67]. In pediatric liver transplantation, basiliximab is being largely used both for preventing rejection and to allow a steroidfree immunosuppression [68].…”

Section: Efficacy Of Basiliximab In Other Organ Transplantsmentioning

confidence: 95%

Basiliximab: efficacy and safety evaluation in kidney transplantation

Ponticelli

2013

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

There is a solid evidence that basiliximab can significantly decrease the risk of acute rejection in kidney transplant recipients without increasing adverse events. This can allow decreased dosage or avoidance of glucocorticoids and reduced dosage of calcineurin inhibitors. On the basis of efficacy, tolerability, ease of administration, and cost effectiveness, basiliximab may be considered the drug of choice for the prophylaxis of acute rejection in standard renal transplant recipients.

show abstract

Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis

Cited by 7 publications

References 21 publications

Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report

Basiliximab: efficacy and safety evaluation in kidney transplantation

Contact Info

Product

Resources

About